$NEPH
NEPHROS INC

2024 Q4 Form 10-Q Financial Statement

#000149315224045793 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $3.518M
YoY Change -5.99%
Cost Of Revenue $1.369M
YoY Change -11.56%
Gross Profit $2.149M
YoY Change -2.05%
Gross Profit Margin 61.09%
Selling, General & Admin $1.721M
YoY Change -19.47%
% of Gross Profit 80.08%
Research & Development $188.0K
YoY Change -8.29%
% of Gross Profit 8.75%
Depreciation & Amortization $33.00K
YoY Change -34.0%
% of Gross Profit 1.54%
Operating Expenses $1.943M
YoY Change -18.94%
Operating Profit $206.0K
YoY Change -201.48%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$23.00K
YoY Change -209.52%
Pretax Income
YoY Change
Income Tax $0.00
% Of Pretax Income
Net Earnings $183.0K
YoY Change -200.55%
Net Earnings / Revenue 5.2%
Basic Earnings Per Share $0.02
Diluted Earnings Per Share $0.02
COMMON SHARES
Basic Shares Outstanding 10.54M shares 10.54M shares
Diluted Shares Outstanding 10.58M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $2.457M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory $3.099M
Prepaid Expenses
Receivables $1.691M
Other Receivables
Total Short-Term Assets $7.356M
YoY Change -13.52%
LONG-TERM ASSETS
Property, Plant & Equipment $173.0K
YoY Change 96.59%
Goodwill $800.0K
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $50.00K
YoY Change -59.35%
Total Long-Term Assets $3.030M
YoY Change 25.57%
TOTAL ASSETS
Total Short-Term Assets $7.356M
Total Long-Term Assets $3.030M
Total Assets $10.39M
YoY Change -4.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $398.0K
YoY Change -50.56%
Accrued Expenses $322.0K
YoY Change -54.78%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.058M
YoY Change -42.12%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.058M
Total Long-Term Liabilities
Total Liabilities $2.212M
YoY Change -3.7%
SHAREHOLDERS EQUITY
Retained Earnings -$144.7M
YoY Change 0.63%
Common Stock $11.00K
YoY Change 10.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity
YoY Change
Total Liabilities & Shareholders Equity $10.39M
YoY Change -4.88%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income $183.0K
YoY Change -200.55%
Depreciation, Depletion And Amortization $33.00K
YoY Change -34.0%
Cash From Operating Activities -$623.0K
YoY Change -209.3%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -623.0K
Cash From Investing Activities 0.000
Cash From Financing Activities 0.000
Net Change In Cash -623.0K
YoY Change -209.3%
FREE CASH FLOW
Cash From Operating Activities -$623.0K
Capital Expenditures $0.00
Free Cash Flow -$623.0K
YoY Change -209.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10292000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10984000 usd
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1369000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1548000 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001196298
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
usd
CY2023Q1 us-gaap Noncontrolling Interest Increase From Subsidiary Equity Issuance
NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
usd
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
usd
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
usd
CY2024Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
usd
CY2024Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
usd
CY2023Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
usd
CY2024Q3 NEPH Finance Lease Cost
FinanceLeaseCost
usd
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-32288
dei Entity Registrant Name
EntityRegistrantName
NEPHROS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3971809
dei Entity Address Address Line1
EntityAddressAddressLine1
380 Lackawanna Place
dei Entity Address City Or Town
EntityAddressCityOrTown
South Orange
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07079
dei City Area Code
CityAreaCode
(201)
dei Local Phone Number
LocalPhoneNumber
343-5202
dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
NEPH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10544225 shares
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.001
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2457000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4307000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1691000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1496000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
3099000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
2470000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
109000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
132000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
7356000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
8405000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
173000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
152000 usd
CY2024Q3 NEPH Operating And Finance Lease Right Of Use Assets
OperatingAndFinanceLeaseRightOfUseAssets
1461000 usd
CY2023Q4 NEPH Operating And Finance Lease Right Of Use Assets
OperatingAndFinanceLeaseRightOfUseAssets
1807000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
357000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
381000 usd
CY2024Q3 us-gaap Goodwill
Goodwill
759000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
759000 usd
CY2024Q3 us-gaap Indefinite Lived License Agreements
IndefiniteLivedLicenseAgreements
230000 usd
CY2023Q4 us-gaap Indefinite Lived License Agreements
IndefiniteLivedLicenseAgreements
271000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
50000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
86000 usd
CY2024Q3 us-gaap Assets
Assets
10386000 usd
CY2023Q4 us-gaap Assets
Assets
11861000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
398000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
873000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
322000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
794000 usd
CY2024Q3 NEPH Operating And Finance Lease Liabilities Current
OperatingAndFinanceLeaseLiabilitiesCurrent
338000 usd
CY2023Q4 NEPH Operating And Finance Lease Liabilities Current
OperatingAndFinanceLeaseLiabilitiesCurrent
446000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1058000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2113000 usd
CY2024Q3 NEPH Operating And Finance Lease Liabilities Non Current
OperatingAndFinanceLeaseLiabilitiesNonCurrent
1154000 usd
CY2023Q4 NEPH Operating And Finance Lease Liabilities Non Current
OperatingAndFinanceLeaseLiabilitiesNonCurrent
1390000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
2212000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
3503000 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10544139 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10544139 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10543675 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10543675 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
11000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
10000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
152844000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
152754000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-144681000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-144406000 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8174000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8358000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10386000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11861000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3518000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3742000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4044000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4600000 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
2149000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
2194000 usd
us-gaap Gross Profit
GrossProfit
6248000 usd
us-gaap Gross Profit
GrossProfit
6384000 usd
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1721000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2137000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5804000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6500000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
188000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
205000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
654000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
665000 usd
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
34000 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
55000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
101000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
163000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
1943000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2397000 usd
us-gaap Operating Expenses
OperatingExpenses
6559000 usd
us-gaap Operating Expenses
OperatingExpenses
7328000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
206000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-203000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-311000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-944000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1000 usd
CY2024Q3 us-gaap Interest Income Other
InterestIncomeOther
20000 usd
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
11000 usd
us-gaap Interest Income Other
InterestIncomeOther
66000 usd
us-gaap Interest Income Other
InterestIncomeOther
36000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-43000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-29000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-23000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
21000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
36000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
23000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
183000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-182000 usd
us-gaap Net Income Loss
NetIncomeLoss
-275000 usd
us-gaap Net Income Loss
NetIncomeLoss
-921000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10544139 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10460866 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10518742 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10352108 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10580906 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10460866 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10518742 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10352108 shares
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8358000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-169000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-9000 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8180000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-289000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
35000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7926000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
183000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
65000 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8174000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8881000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-306000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
319000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8894000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-433000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
194000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8655000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8655000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-182000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-182000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
149000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8622000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8622000 usd
us-gaap Net Income Loss
NetIncomeLoss
-275000 usd
us-gaap Net Income Loss
NetIncomeLoss
-921000 usd
us-gaap Depreciation
Depreciation
34000 usd
us-gaap Depreciation
Depreciation
29000 usd
us-gaap Amortization Of Deferred Charges
AmortizationOfDeferredCharges
68000 usd
us-gaap Amortization Of Deferred Charges
AmortizationOfDeferredCharges
134000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
91000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
662000 usd
us-gaap Inventory Write Down
InventoryWriteDown
214000 usd
us-gaap Inventory Write Down
InventoryWriteDown
106000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
14000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-1000 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
5000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
195000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
171000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
843000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-778000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-23000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-15000 usd
NEPH Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-364000 usd
NEPH Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-234000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-36000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
69000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-477000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
65000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-470000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
425000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-362000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-237000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1796000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1064000 usd
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
5000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
55000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-50000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
4000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
4000 usd
NEPH Principal Payments On Equipment Financing
PrincipalPaymentsOnEquipmentFinancing
1000 usd
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
71000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-76000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1850000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
988000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4307000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3634000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2457000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4622000 usd
us-gaap Interest Paid Net
InterestPaidNet
1000 usd
us-gaap Interest Paid Net
InterestPaidNet
6000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
22000 usd
us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_806_eus-gaap--NatureOfOperations_z1vv29399L6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_825_zbAmZtxyyVFa">Organization and Nature of Operations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 29.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nephros, Inc. (“Nephros” or the “Company”) was incorporated under the laws of the State of Delaware on April 3, 1997. The Company was founded by health professionals, scientists and engineers affiliated with Columbia University to develop advanced end stage renal disease (“ESRD”) therapy technology and products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning in 2009, Nephros introduced high performance liquid purification filters to meet the demand for water purification in certain medical markets. The Company’s filters, generally classified as ultrafilters, are primarily used in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate. The Company also develops and sells water filtration products for commercial applications, focusing on the hospitality and food service markets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2018, the Company formed a subsidiary, Specialty Renal Products, Inc. (“SRP”), to drive the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. After SRP’s formation, the Company assigned to SRP all of the Company’s rights to three patents relating to the Company’s hemodiafiltration technology, which were carried at zero book value. On March 9, 2023, the SRP Stockholders approved a plan of dissolution to wind down SRP’s operations, liquidate SRP’s remaining assets and dissolve SRP, and SRP filed a certificate of dissolution with the State of Delaware on April 13, 2023. As a result of the SRP Stockholders’ approval of the plan of dissolution and provisions therein and after satisfying all of SRP’s liabilities, there are no assets available for distribution to the holders of any of SRP’s capital stock, including its Series A Preferred Stock. As such, the value recorded to non-controlling interest was written to zero and the impact reclassified to the Company’s additional paid-in capital as the Company retained control of SRP.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s primary U.S. facility is located at 380 Lackawanna Place, South Orange, New Jersey 07079. This location along with our Whippany, NJ facility, houses the Company’s corporate headquarters, research, manufacturing, and distribution facilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84F_eus-gaap--UseOfEstimates_z1EfsUtckiFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amount of revenues and expenses, during the reporting period. Actual results could differ materially from those estimates. Included in these estimates are assumptions about the collection of accounts receivable, value of inventories, useful life of fixed assets and intangible assets, the assessment of expected cash flows used in evaluating goodwill and other long-lived assets, the assessment of the ability to continue as a going concern and assumptions used in determining stock compensation such as expected volatility and risk-free interest rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1100000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1800000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-144700000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zK6Tf04eJi6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentration of Credit Risk</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company deposits its cash in financial institutions. At times, such deposits may be in excess of insured limits. To date, the Company has not experienced any impairment losses on its cash. The Company also limits its credit risk with respect to accounts receivable by performing credit evaluations when deemed necessary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
11000 usd
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
14000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2024Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2023Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2730000 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2144000 usd
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
369000 usd
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
326000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
3099000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
2470000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
540000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-183000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
357000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
540000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-159000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
381000 usd
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8000 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
24000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
31000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
8000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
32000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
32000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
32000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
32000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
32000 usd
CY2024Q3 us-gaap Goodwill
Goodwill
800000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
800000 usd
CY2024Q3 us-gaap Finite Lived License Agreements Gross
FiniteLivedLicenseAgreementsGross
2300000 usd
CY2023Q4 us-gaap Debt Instrument Description Of Variable Rate Basis
DebtInstrumentDescriptionOfVariableRateBasis
EURIBOR 360-day rate plus 500 basis points calculated on the principal amount of any outstanding invoices that are overdue by more than 15 days beyond the original payment terms.
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
112000 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
90000 usd
CY2023Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2000 usd
CY2023Q3 NEPH Finance Lease Cost
FinanceLeaseCost
2000 usd
CY2024Q3 us-gaap Variable Lease Cost
VariableLeaseCost
37000 usd
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
2000 usd
CY2024Q3 us-gaap Lease Cost
LeaseCost
149000 usd
CY2023Q3 us-gaap Lease Cost
LeaseCost
94000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
364000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
272000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
4000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
6000 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
2000 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
2000 usd
NEPH Finance Lease Cost
FinanceLeaseCost
6000 usd
NEPH Finance Lease Cost
FinanceLeaseCost
8000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
62000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
9000 usd
us-gaap Lease Cost
LeaseCost
432000 usd
us-gaap Lease Cost
LeaseCost
289000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
456000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
272000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
4000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
4000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1438000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1803000 usd
CY2024Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
23000 usd
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
4000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
333000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
442000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1136000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1390000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1469000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1832000 usd
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
5000 usd
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
4000 usd
CY2024Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
18000 usd
CY2024Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
23000 usd
CY2023Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
4000 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M18D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y3M18D
CY2024Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D
CY2023Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y7M6D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080 pure
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080 pure
CY2024Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.080 pure
CY2023Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.080 pure
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
107000 usd
CY2024Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
1000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
435000 usd
CY2024Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
7000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
450000 usd
CY2024Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
7000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
450000 usd
CY2024Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
7000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
251000 usd
CY2024Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
5000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1693000 usd
CY2024Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
27000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
224000 usd
CY2024Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
4000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1469000 usd
CY2024Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
23000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
555000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
183000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-182000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10544139 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10460866 shares
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
36767
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10580906 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10460866 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Net Income Loss
NetIncomeLoss
-275000 usd
us-gaap Net Income Loss
NetIncomeLoss
-921000 usd
us-gaap Net Income Loss
NetIncomeLoss
-275000 usd
us-gaap Net Income Loss
NetIncomeLoss
-921000 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10518742 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10352108 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10518742 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10352108 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001493152-24-045793-index-headers.html Edgar Link pending
0001493152-24-045793-index.html Edgar Link pending
0001493152-24-045793.txt Edgar Link pending
0001493152-24-045793-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
neph-20240930.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
neph-20240930_cal.xml Edgar Link unprocessable
neph-20240930_def.xml Edgar Link unprocessable
neph-20240930_lab.xml Edgar Link unprocessable
neph-20240930_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable